论文部分内容阅读
目的观察丹参酮ⅡA治疗川崎病(KD)的临床效果。方法将61例住院KD患儿随机分为对照组和治疗组,其中对照组32例,给予常规治疗(静脉丙种球蛋白+阿司匹林);治疗组29例,在对照组治疗的基础上加用丹参酮ⅡA治疗5～7 d。观察治疗过程中患儿的临床症状、体征、超声心动图、CRP、ESR、心肌同工酶变化情况。结果治疗组患儿用药后热退时间为(16.27±3.42)h,对照组患儿为(22.78±7.53)h,2组比较差异有统计学意义(P<0.05);用药后治疗组CRP降至(9.72±2.82)mg.L-1,对照组患儿CRP降至(14.68±2.90)mg.L-1,2组比较差异有统计学意义(P<0.05);治疗组、对照组在疾病初诊时冠状动脉扩张率分别为20.69%、21.88%,2组比较差异无统计学意义(P>0.05),病程2～3周、1个月、2个月治疗组冠状动脉扩张率分别为6.90%、3.45%、3.45%,在病程3个月冠状动脉扩张全部恢复正常;在病程2～3周、1个月、2个月、3个月、6个月,对照组冠状动脉扩张率分别为18.75%、12.50%、3.13%、3.13%、3.13%,治疗组较对照组患儿冠状动脉扩张恢复的快,但2组比较差异尚无统计学意义(P>0.05)。结论丹参酮ⅡA联合阿司匹林治疗KD可缩短患儿用药后热退时间,降低CRP水平,一定程度的促进冠状动脉损害修复;用药过程未发现明显的不良反应。
Objective To observe the clinical effect of tanshinone Ⅱ A in treating Kawasaki disease (KD). Methods Sixty-one hospitalized children with KD were randomly divided into control group and treatment group, of which 32 cases in control group were given conventional therapy (intravenous gamma globulin plus aspirin). In treatment group, 29 cases were treated with tanshinone Ⅱ A treatment of 5 to 7 days. The clinical symptoms, signs, echocardiography, CRP, ESR and myocardial isoenzyme in children during the treatment were observed. Results After treatment, the thermal back-off time was (16.27 ± 3.42) h in the treatment group and (22.78 ± 7.53) h in the control group, the difference was statistically significant between the two groups (P <0.05) (9.72 ± 2.82) mg.L-1, the CRP in control group decreased to (14.68 ± 2.90) mg.L-1 and 2, the difference was statistically significant (P <0.05) Coronary artery dilatation rates were 20.69% and 21.88%, respectively. There was no significant difference between the two groups (P> 0.05). The duration of coronary artery dilation was 2 ~ 3 weeks, 1 month and 2 months respectively 6.90%, 3.45% and 3.45% respectively. All the coronary artery dilatation returned to normal within 3 months of course of disease. In the course of 2 ~ 3 weeks, 1 month, 2 months, 3 months and 6 months, Respectively, which were 18.75%, 12.50%, 3.13%, 3.13% and 3.13% respectively. The recovery of coronary artery in the treatment group was faster than that in the control group, but there was no significant difference between the two groups (P> 0.05). Conclusion Tanshinone Ⅱ A combined with aspirin in the treatment of KD can shorten the treatment of children with thermal back-up time, reduce the level of CRP, to some extent, promote the repair of coronary lesions; medication was not found significant adverse reactions.